See All Slides - tctmd.com

Slides

Presentation TCT 2015

Debate: The Case for Short-term DAPT in Most Patients!

Presenter: Regina Deible, Gennaro Giustino

October 11, 2015

Presentation TCT 2015

Stroke and Bleeding Risk Scores: How to Use These in Practice

Presenter: Russell A. Brandwein, Brian K. Whisenant

October 11, 2015

Presentation TCT 2015

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Presenter: Thomas Engstroem, Barry D. Rutherford, Colin Berry

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

How to Handle Outliers in the Lab

Presenter: Michael A. Kutcher, Sunil V. Rao

October 11, 2015

Presentation TCT 2013

Identifying and Managing Embolic-Prone Lesions: RF-IVUS, OCT, and NIRS

Presenter: Emmanouil Brilakis

October 31, 2013

Presentation TCT 2013

What Is Ischemia? Is There a Gold Standard, and How Should New Modalities Be Evaluated?

Presenter: Habib Samady

October 31, 2013

Presentation TCT 2013

Genetic Testing is of Clear Clinical Utility in Selected Patients

Presenter: Jessica Mega

October 31, 2013

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

Case I: Transseptal Antegrade Approach to a Mitral Valve PVL

Presenter: Paul Sorajja

October 31, 2013

Advertisement

Slides

Debate: The Case for Short-term DAPT in Most Patients!

Stroke and Bleeding Risk Scores: How to Use These in Practice

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

How to Handle Outliers in the Lab

Identifying and Managing Embolic-Prone Lesions: RF-IVUS, OCT, and NIRS

What Is Ischemia? Is There a Gold Standard, and How Should New Modalities Be Evaluated?

Genetic Testing is of Clear Clinical Utility in Selected Patients

Mortality Trumps All: Ticagrelor for (Nearly) All!

Case I: Transseptal Antegrade Approach to a Mitral Valve PVL

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content